Acute naphthalene poisoning following the non-accidental ingestion of mothballs

Lim H C, Poulose V, Tan H H

ABSTRACT
Ingestional naphthalene mothball poisoning leading to prolonged haemolysis and methaemoglobinemia can present with diagnostic and therapeutic challenges. A 19-year-old woman ingested 12 mothballs, and presented two days later with haemolysis and methaemoglobinemia. She was treated with red blood cell transfusions, intravenous methylene blue, N-acetylcysteine and ascorbic acid. Continuous venovenous haemofiltration was conducted for 45 hours. Haemolysis with anaemia and methaemoglobinemia persisted even after five days post-ingestion. Clinical and biochemical parameters improved. We describe a case of ingestion naphthalene poisoning with a good outcome after treatment.

Keywords: haemolysis, methaemoglobinemia, mothball ingestion, naphthalene, poisoning

INTRODUCTION
Naphthalene mothballs, as a choice agent for deliberate ingestion in suicide, is uncommon in Singapore. Other more common agents that have led to patients requiring intensive care include organophosphates and carbamates, benzodiazepines, tricyclic antidepressants, and phenothiazine.\(^2\) The fatal dose for naphthalene in humans is unknown, but as little as one mothball can result in toxicity in children. Deaths have been reported following ingestion of naphthalene balls.\(^3\) Haemolytic anaemia and methaemoglobinemia from poisoning can pose a diagnostic and therapeutic challenge to clinicians because it is not commonly encountered. We present a case of prolonged naphthalene-induced haemolysis and methaemoglobinemia from a non-accidental ingestion of 12 naphthalene mothballs, and reviewed the mechanism of its toxicity, diagnostic dilemma and management recommendations.

CASE REPORT
A 19-year-old female foreign student presented 40 hours after intentional oral ingestion of 12 mothballs. This was due to school stress. She did not have any past medical history. She complained of giddiness and dark-coloured urine a few hours after the ingestion, but only sought medical help because of persistent symptoms. On the day of presentation, she vomited once and had mild suprapubic pain. Clinically, she was eufibrile, her pulse rate was 109/minute, respiratory rate 16/minute, blood pressure 102/71 mmHg, oxygen saturation (SpO2) 82% on 100% oxygen via facemask. She was pale, jaundiced and appeared to have cyanosis. Heart sounds were dull with a grade 2/6 ejection systolic murmur heard at the heart apex. The lungs were clear with good air entry bilaterally. The abdomen was mildly tender in the suprapubic region, but soft and not guarded. No organomegaly was noted. Neurological examination was normal.

Urinary catheterisation collected dark-brown urine, which tested positive for blood on dipstick. The urine microscopy did not reveal significant red blood cells (RBC) content or casts, suggesting haemoglobinuria. Electrocardiogram showed normal sinus rhythm, with no ischaemic changes. At that time, the provisional diagnosis was haemolysis, haemoglobinuria and possibly methaemoglobinemia secondary to naphthalene toxicity. She did not bring any remaining mothball for examination. Supportive management with oxygen and intravenous (IV) fluid was provided. Gastric washout and activated charcoal administration were not performed in view of delayed presentation. Alkalisation of urine was initiated in the emergency department in an effort to prevent renal tubular damage, and she was admitted to the intensive care unit (ICU) for further management. Alkalisation of urine was continued there.

Her initial full blood count revealed haemoglobin (Hb) 9.7 g/dL with haematocrit 27.4%, reticulocyte count 0.8%, total white cell count 26.6 x 10\(^3\)μL, and neutrophil 84.1%. Intravascular haemolysis was confirmed by serum jaundice with total bilirubin measuring 84.0 μmol/L and a highly-raised indirect bilirubin level, associated with low serum haptoglobin 0.09 g/L. Her platelet count and coagulation profile were normal. Renal function and the serum creatinine kinase were also normal. Liver enzyme aspartate transaminase was raised at 98 U/L, but alkaline phosphatase and alanine transaminase were normal. Arterial blood gas (ABG) analysis did not reveal...
any acidosis; pH 7.423, pCO₂ 34.4 mmHg, pO₂ 380.0 mmHg, base excess -1.7 mmol/L, HCO₃ 21.9, O₂ Sat 100.0%. Serum lactic acid was normal.

Her first methaemoglobin (MetHb) level was 9.6% (Hb 8.6 g/dL). This increased to 13% on the second day of admission, with Hb dropping to 7.5 g/dL. IV methylene blue 60 mg (1.5 mg/kg) was prescribed on Day two of admission and she was transfused two units of RBC concentrate (total 730 ml). Oral ascorbic acid 300 mg and N-acetylcysteine (NAC) 1.2 g daily was started. On Day 3 of admission, the Hb remained at 7.5 g/dL, and there was only some improvement of MetHb to 7.8%. Ongoing haemolysis was suspected based on the failure of Hb to improve as well as the continued collection of dark-brown urine. Another two units of blood (total 780 ml) were transfused and continuous renal replacement therapy (CRRT) in the form of continuous venovenous haemofiltration (CVVH) was started. This continued for almost 45 hours till Day 5. Blood samples on Days 1 and 3 of admission were qualitatively positive for naphthalene; however, the urine sample on Day 1 was negative for naphthalene. On Day 4, her laboratory parameters improved. Hb stabilised at 9.4 g/dL without further blood transfusion; total bilirubin had dropped from 77.6 to 38.5 μmol/L, with AST in the downward trend as well. Her renal function remained normal and alkaline diuresis was stopped. The urine was noted to be clear, and there was decreased cyanosis. The pulse oximeter began to register consistently > 95% by late afternoon that day.

At this time, blood glucose-6-phosphate dehydrogenase (G6PD) activity was confirmed present, and her Hb electrophoresis was suggestive of Hb-E alpha thalassemia. By Day 5 of admission, her Hb level had stabilised at 9.8 g/dL with normalisation of leucocyte count and serum total bilirubin level. Renal function was preserved and MetHb was reduced to 1.8%. CVVH was discontinued and she was sent to general ward after five days in the ICU. Radiography tests for her abdominal pain were normal and her urine pregnancy test was negative. The pain resolved spontaneously. She stayed a total of ten days in the hospital. On discharge, her Hb was 10.3 g/dL and MetHb 1.1%, with no renal or neurological sequelae. Subsequently, she was lost to outpatient follow-up. Table I and Fig. 1 illustrate the progression of her biochemical parameters and the important interventions performed while she was admitted.

**DISCUSSION**

Mothballs retailed for household use in Singapore may contain naphthalene or paradichlorobenzene, of which the latter poses less harm if ingested. Camphor mothballs are not freely available in Singapore. Bedside differentiation is important to the clinician because identifying a mothball containing paradichlorobenzene can often lead to outpatient management, saving both money and undue worry. One method is to test the ability of the mothball to float in water and concentrated salt solution. A naphthalene mothball floats in saturated salt solution but sinks in water. If it sinks in both liquids, it is a paradichlorobenzene mothball. Camphor, in contrast, floats on water. Radiography may also be helpful as paradichlorobenzene is radiopaque whereas naphthalene is not.

Naphthalene is a bicyclic aromatic hydrocarbon with a molecular weight of 128 (C₁₀H₈). It is poorly soluble in water, and one mothball (depending on size) can contain between 0.5–5 g of naphthalene. The clinical consequences of naphthalene ingestion may include headache, vomiting, diarrhoea, abdominal pain, fever and altered mental status. Oxidative stress from the hepatic metabolites of naphthalene causes haemolysis and methaemoglobinemia. The presence of one should prompt the exclusion of the other. Laboratory studies have also demonstrated that naphthalene induces toxic manifestations by enhanced production of free oxygen radicals, resulting in lipid peroxidation and deoxyribonucleic acid damage. Ascorbic acid was given to our patient to counteract this effect; it has also been used in one previously-described case, though its efficacy is questioned as it is a weak reducing agent.

Haemolysis occurs through either Hb (Heinz bodies formation) or cell membrane effects, particularly in patients with a low tolerance to oxidative stress (G6PD deficiency). Renal failure as a complication of naphthalene-induced haemolysis and haemoglobinuria
has been reported. Haemolysis and haemoglobinuria are treated with IV hydration ensuring brisk urine output, urinary alkalinisation and packed RBC transfusion. Urinary alkalinisation and IV hydration with diuresis are aimed at minimising the deposition of Hb in kidney tubules. However, regular monitoring and correction of blood and urine pH as well as blood electrolytes need to be maintained.

Methaemoglobinaemia is caused by the oxidation of ferrous (Fe^{2+}) to ferric (Fe^{3+}) Hb. It renders the Hb incapable of carrying oxygen and shifts the oxyhaemoglobin curve to the left. Cyanosis is clinically detectable at >10% metHb in a patient with a Hb 15 g/dL (> 1.5 g/dL of metHb). However, the presence of anaemia could mask this clinical sign at the same metHb fraction. Pulse oximetry may become unreliable in the setting of methaemoglobinaemia, registering a false high in patients with severe methaemoglobinaemia and a false low in patients with mild methaemoglobinaemia.

Routine ABG of these patients measures serum PO2 (which is normal) and calculates a falsely normal oxygen saturation. A co-oximeter type of blood gas analyser is needed to directly measure the oxygen saturation and metHb levels. Clinical suspicion of metHb should be raised when there is cyanosis that does not respond to high-flow oxygen with no obvious cardiorespiratory causes, like right-to-left shunting.

Standard treatment includes the use of methylene blue and exchange transfusion. Methylene blue increases the rate of conversion of metHb to Hb by accepting an electron (in the presence of nicotinamide adenine dinucleotide phosphate [NADPH] and metHb reductase), to form leucumethylene blue, which can then donate this electron to reduce metHb. It is important to note that methylene blue itself may induce haemolysis (through the development of Heinz bodies) and cause paradoxical methaemoglobinaemia, especially in G6PD deficient patients. The use of NAC as a direct reducing agent in treating methaemoglobinaemia is still being investigated. It presents the potential benefit in G6PD deficiency because glutathione synthesis is not dependent on NADPH. However, recent studies with NAC failed to show enhanced reduction in human volunteers. Other than the specific therapies described above, management of naphthalene toxicity is mainly supportive. If the patient presents early, decontamination procedures like the use of activated charcoal, gastric lavage and whole bowel irrigation should be considered.

Our patient demonstrated persistent haemolytic anaemia and methaemoglobinaemia up to five days post-ingestion. This is also shown in other cases of naphthalene ingestion where the haemolysis and metHb persisted more than a week. No studies have quantified the rate and extent of naphthalene absorption in humans following ingestion. Extended urinary excretion has been observed following the ingestion, with metabolites still detectable in the urine 13 days post-ingestion. The postmortem finding of one patient who swallowed 40 mothballs and died five days later revealed 25 remaining mothballs in the stomach.

There is little in the literature on the use of extracorporeal elimination modalities to treat acute poisoning with naphthalene. One man with naphthalene poisoning had survived following haemodialysis. Free naphthalene and its metabolites should cross the haemofilter readily, but naphthalene is poorly watersoluble, and its volume of distribution is not defined. The role of CRRT in the removal of excessive fluid overload, especially in haemodynamically-unsuitable patients, is well established. However, its role in poison elimination remains ill-defined. Its use in lithium poisoning to reduce the rebound of lithium level post-haemodialysis has been reported. This is mainly because CRRT can be used over 24 hours. The CRRT technique to enhance elimination was utilised in this case because of continued haemolysis despite full supportive care and blood transfusion. In the presence of delayed extended absorption of naphthalene from the gastrointestinal tract or sequestration of the poison in the body fats, it could provide ongoing removal of toxins, reducing the likelihood of rebound toxicity. The institution of CVVH coincided with clinical improvement in our patient. However, we could not confirm whether it made a real difference in the patient’s recovery, and more studies

---

### Table I. Progression of biochemical parameters while the patient was admitted.

<table>
<thead>
<tr>
<th>Day of admission:</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>Day 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin (g/dL)</td>
<td>8.6</td>
<td>7.5</td>
<td>7.5</td>
<td>9.4</td>
<td>9.8</td>
<td>10.3</td>
</tr>
<tr>
<td>Methaemoglobin (%)</td>
<td>9.6</td>
<td>13</td>
<td>7.8</td>
<td>NA</td>
<td>1.8</td>
<td>1.1</td>
</tr>
<tr>
<td>Qualitative serum naphthalene</td>
<td>Positive</td>
<td>ND</td>
<td>Positive</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Urine colour</td>
<td>Brown</td>
<td>Brown</td>
<td>Brown</td>
<td>Clear</td>
<td>Clear</td>
<td>NA</td>
</tr>
</tbody>
</table>

NA: not available; ND: not done

---

need to be done before it could be recommended as a modality of treatment for naphthalene poisoning.

In summary, naphthalene mothball ingestion can present with prolonged haemolytic anaemia and methaemoglobinemia. Overdose by this poison is uncommon but can prove fatal, especially in patients who are G6PD deficient. The diagnostic challenge to clinicians attending to patients who present with pallor, jaundice and cyanosis that do not respond to oxygen therapy should include poisoning by oxidising agents like naphthalene. The early use of decontamination procedure as well as judicious use of antidotes (methylene blue) should be considered in the management of these patients, besides the standard supportive management, including blood transfusion and exchange transfusion. Enhanced elimination techniques like CRRT could be considered, but it still remains unproven, and hence cannot be routinely recommended.

REFERENCES